Host: Insect cells • AA: 686-1,213 • Tag: C-terminal mouse IgG1 Fc • MW: 84.33 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV-2 Spike Glycoprotein S2 Subunit (recombinant)

Item No. 31815

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • 2019-nCoV Surface Glycoprotein S2 Subunit
  • COVID-19 Spike Glycoprotein S2 Subunit
  • SARS-CoV-2 Spike Glycoprotein S2 Subunit
  • Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein S2 Subunit
Purity
≥95% estimated by SDS-PAGE
Endotoxin Testing
<1.0 EU/g determined by the LAL endotoxin assay
Source
Recombinant C-terminal mouse IgG1 Fc-tagged SARS-CoV-2 surface glycoprotein S2 subunit expressed in insect cells
Amino Acids
686-1,213
MW
84.3 kDa
Formulation (Request formulation change)
Lyophilized from sterile 20 mM Tris, pH 7.0, 300 mM sodium chloride, and 100 mM glycine
Host
Insect cells
UniProt Accession №
P0DTC2
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $543

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus, a member of the Betacoronavirus genus, and the causative agent of COVID-19.1,2,3,4,5 The SARS-CoV-2 spike glycoprotein, also known as the surface glycoprotein, is a viral structural protein encoded by the S gene in SARS-CoV-2 RNA.1 It is composed of an S1 and S2 subunit divided by a furin S-cleavage site not found in other SARS-CoVs.6,7 The C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes, contains a fusion peptide (FP) and two heptad repeats (HRs), as well as transmembrane and cytoplasmic domains.7,8 Upon insertion of the FP in the target cell membrane, the HRs form a six-helical bundle (6-HB) that enables SARS-CoV-2 to fuse with the target cell. The SARS-CoV-2 spike glycoprotein S2 subunit increases amyloid-β (1-40) (Aβ40) and Aβ42 levels in primary mouse neuron culture supernatants and the number of hippocampal and cortical Aβ plaques in APPswe/PSEN1dE9 transgenic mice.9 Cayman's SARS-CoV-2 Spike Glycoprotein S2 Subunit (recombinant) protein is a disulfide-linked homodimer. The reduced monomer, composed of the SARS-CoV-2 spike glycoprotein S2 subunit (amino acids 686-1,213) fused to mouse IgG1 Fc at its C-terminus, consists of 762 amino acids and has a calculated molecular weight of 84.3 kDa.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et al. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et al. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    4. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).

    5. Yang, F., Shi, S., Zhu, J., et al. Analysis of 92 deceased patients with COVID-19. J. Med. Virol. 92(11), 2511-2515 (2020).

    6. Liu, Z., Xiao, X., Wei, X., et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J. Med. Virol. 92(6), 595-601 (2020).

    7. Walls, A.C., Park, Y.-J., Tortorici, M.A., et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2), 281-292 (2020).

    8. Huang, Y., Yang, C., Xu, X.-F., et al. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41(9), 1141-1149 (2020).

    9. Ma, G., Zhang, D.-F., Zou, Q.-C., et al. SARS-CoV-2 Spike protein S2 subunit modulates γ-secretase and enhances amyloid-β production in COVID-19 neuropathy. Cell Discov. 8(1), 99 (2022).